TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21338898

Group type: EXPERIMENTAL
Intervention: Parental reproductive health (RH) knowledge
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Parental comfort of communication
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Frequency of talk
Number of subjects: 185

Group type: COMPARATOR
Intervention: Parents' discordant perceptions regarding their child's reported involvement in relationships
Number of subjects: 185
Study: 19240944

Group type: EXPERIMENTAL
Intervention: Yondelis (trabectedin, ET-743)
Number of subjects: 0
Study: 17317021

Group type: EXPERIMENTAL
Intervention: 50 microg ghrelin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15054370

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 0
Study: 11760616

Group type: EXPERIMENTAL
Intervention: Psychologist-led preventive intervention
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Teacher-led preventive intervention
Number of subjects: 489

Group type: COMPARATOR
Intervention: Usual care (standard curriculum) with monitoring
Number of subjects: 489
Study: 9479614

Group type: EXPERIMENTAL
Intervention: d,l-fenfluramine (FEN) 60 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: lithium
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: carbamazepine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: drug-free unipolar patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: nonresponders
Number of subjects: 17
Study: 7524593

Group type: EXPERIMENTAL
Intervention: C1 inhibitor plasma concentrate 3000 U i.v.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study: 3555690

Group type: EXPERIMENTAL
Intervention: Dipyridamole 200 mg b.d. for 48 h pre-operatively and dipyridamole 200 mg b.d. with aspirin 300 mg daily for 6 weeks after surgery
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Prosthetic dipyridamole and aspirin group
Number of subjects: 148

Group type: COMPARATOR
Intervention: Prosthetic control group
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Dipyridamole and aspirin group
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 148
Study: 30753323

Group type: EXPERIMENTAL
Intervention: Cashew nut phase (1.5 servings or 42 g of cashews/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control phase (no additions to the base diet)
Number of subjects: 42
Study: 29102979

Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg once daily
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 25232958

Group type: EXPERIMENTAL
Intervention: Mouthwash containing 1% Chamomilla recutita extract
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mouthwash containing 0.5% and 2% Chamomilla recutita extract
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care alone (control group)
Number of subjects: 40
Study: 23051876

Group type: EXPERIMENTAL
Intervention: Enterostomal nurse telephone follow-up (2-3 calls during follow-up period)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Routine discharge care (control group)
Number of subjects: 103
Study: 22097346

Group type: EXPERIMENTAL
Intervention: Spleen-restoring decoction combined with dormancy hygiene education (A group)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Spleen-restoring decoction alone (B group)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both interventions (A and B groups)
Number of subjects: 107
Study: 20015430

Group type: EXPERIMENTAL
Intervention: Tunnel thread-drawing therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Multiple incisions and drainage (Control)
Number of subjects: 68
Study: 17047542

Group type: EXPERIMENTAL
Intervention: Manual Physical Therapy, Exercise, and Walking Group
Number of subjects: 58

Group type: COMPARATOR
Intervention: Flexion Exercise and Walking Group
Number of subjects: 58
Study: 15008862

Group type: EXPERIMENTAL
Intervention: Chromated glycerin (CG)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Polidocanol (POL) 0.25% solution
Number of subjects: 150

Group type: COMPARATOR
Intervention: Polidocanol (POL) 0.25% foam
Number of subjects: 150
Study: 11489037

Group type: EXPERIMENTAL
Intervention: Randomized double-blind clinical trial (RDBCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring and accounting for experimenter beliefs and expectations
Number of subjects: 0
Study: 9215605

Group type: EXPERIMENTAL
Intervention: Itasetron hydrochloride (0.5, 1, 2, 4, and 8 mg twice daily)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Ondansetron (8 mg twice daily)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Itasetron hydrochloride
Number of subjects: 104

Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 104
Study: 7977542

Group type: EXPERIMENTAL
Intervention: Prenatal smoking cessation interventions
Number of subjects: 11
Study: 3301986

Group type: EXPERIMENTAL
Intervention: Polymerized ragweed (PRW) immunotherapy, 15 weekly injections totaling 1359 allergy units
Number of subjects: 81

Group type: COMPARATOR
Intervention: Caramelized glucose histamine placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Polymerized ragweed (PRW) immunotherapy
Number of subjects: 81
Study: 29608659

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 461

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 461
Study: 27272893

Group type: EXPERIMENTAL
Intervention: Trans-sylvian SAH
Number of subjects: 48

Group type: COMPARATOR
Intervention: Temporobasal SAH
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 24631977

Group type: EXPERIMENTAL
Intervention: Naturalistic conversation during driving under lorazepam
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: No conversation during driving under lorazepam
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo condition with no conversation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Self-assessment of driving performance before the drive
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Self-assessment of driving performance during or after the drive
Number of subjects: 16
Study: 22198971

Group type: EXPERIMENTAL
Intervention: Implicit religion priming
Number of subjects: 0

Group type: COMPARATOR
Intervention: No religion priming
Number of subjects: 0
Study: 19368912

Group type: EXPERIMENTAL
Intervention: 300 IU of rFSH (group A)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 450 IU of rFSH (group B)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 600 IU of rFSH (group C)
Number of subjects: 119
Study: 18705320

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBO), started 3 days after operation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no HBO treatment)
Number of subjects: 14
Study: 17286120

Group type: EXPERIMENTAL
Intervention: Blurred natural scenes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local motion information
Number of subjects: 0
Study: 12831383

Group type: EXPERIMENTAL
Intervention: Primary care buprenorphine treatment
Number of subjects: 115

Group type: COMPARATOR
Intervention: Specialist clinic buprenorphine treatment
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 115
Study: 11573756

Group type: EXPERIMENTAL
Intervention: CD-ROM nutrient database
Number of subjects: 42

Group type: COMPARATOR
Intervention: Food record booklet
Number of subjects: 42
Study: 8156354

Group type: EXPERIMENTAL
Intervention: Octreotide 0.1 mg every 8 h
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 2901251

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30419125

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 27
Study: 28541887

Group type: EXPERIMENTAL
Intervention: videos with text messages
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: videos only
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: text messages-only
Number of subjects: 90

Group type: COMPARATOR
Intervention: standard of care
Number of subjects: 90
Study: 26255876

Group type: EXPERIMENTAL
Intervention: Surgical treatment for excessive gingival exposure by septum cartilage reinforcement and additional extension using an autologous cartilage graft or ePTFE implant.
Number of subjects: 121

Group type: COMPARATOR
Intervention: Nasal septum dysplasia as an etiologic factor for gummy smile.
Number of subjects: 121
Study: 23893461

Group type: EXPERIMENTAL
Intervention: Trametinib (2 mg) administered in a fed state
Number of subjects: 24

Group type: COMPARATOR
Intervention: Trametinib (2 mg) administered in a fasted state
Number of subjects: 24
Study: 20063106

Group type: EXPERIMENTAL
Intervention: Opioid (1 microg/kg of fentanyl intravenously)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 27
Study: 18780182

Group type: EXPERIMENTAL
Intervention: Implementation of the positive action program (amount of curriculum delivered and use of program-specific materials)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Teachers' attitudes toward the program
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Teachers' beliefs about SACD
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Perceptions of school climate
Number of subjects: 362
Study: 17000959

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a 44 microg subcutaneously three times weekly (TIW)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a 22 microg subcutaneously three times weekly (TIW)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo (initially randomized group)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 560
Study: 12730744

Group type: EXPERIMENTAL
Intervention: Direct access DXA scanning (DADS)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Current system of specialist referral (controls)
Number of subjects: 330
Study: 11097538

Group type: EXPERIMENTAL
Intervention: Intraoperative morphine (0.1 mg x kg(‐1))
Number of subjects: 70

Group type: COMPARATOR
Intervention: Postoperative morphine (0.1 mg x kg(‐1))
Number of subjects: 70
Study: 8760978

Group type: EXPERIMENTAL
Intervention: PTA plus medical treatment (n = 30)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Medical treatment alone (control group, n = 32)
Number of subjects: 42
Study: 1581268

Group type: EXPERIMENTAL
Intervention: Bupivacaine with epinephrine (5 micrograms/ml)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bupivacaine without epinephrine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Unilateral pleural infusion of bupivacaine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bilateral pleural infusion of bupivacaine
Number of subjects: 16
Study: 30796054

Group type: EXPERIMENTAL
Intervention: Modified Goldmann prism
Number of subjects: 243

Group type: COMPARATOR
Intervention: Standard Goldmann prism
Number of subjects: 243
Study: 29851120

Group type: EXPERIMENTAL
Intervention: Partially group‐function occlusion (PGFO)
Number of subjects: 30
Study: 26685154

Group type: EXPERIMENTAL
Intervention: Semmes-Weinstein monofilament test
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Static two-point discrimination test
Number of subjects: 67
Study: 27129118

Group type: EXPERIMENTAL
Intervention: SFDAC intranasal spray (up to 3,200 µg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22121129

Group type: EXPERIMENTAL
Intervention: golimumab 50 mg + MTX (Group 2)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + MTX (Group 3)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: combined Groups 2 and 3
Number of subjects: 269

Group type: COMPARATOR
Intervention: placebo + MTX (Group 1)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: golimumab + MTX
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Groups 1, 2, and 3
Number of subjects: 269
Study: 19945102

Group type: EXPERIMENTAL
Intervention: Surgical treatment with an angular stable interlocking implant (25 patients)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conservative treatment (25 patients)
Number of subjects: 50
Study: 17380402

Group type: EXPERIMENTAL
Intervention: Bowel preparation consisting of an isotonic solution containing polyethylene glycol and simethicone (200 ml given 30 min before capsule, followed by 100 ml of prep and 100 ml of water; additional 100 ml of prep given 45 and 75 min later)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control administration of 100 ml of water and no simethicone
Number of subjects: 9
Study: 15598683

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-fat meal
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate meal
Number of subjects: 50
Study: 12150229

Group type: EXPERIMENTAL
Intervention: Actors' perspective taking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observers' correspondent inferences
Number of subjects: 0
Study: 10434485

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) at an average dose of 0.5 mg/kg twice daily
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 91
Study: 8871266

Group type: EXPERIMENTAL
Intervention: Policosanol 5 mg twice-a-day
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 2273545

Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride 2 mg in 8 ml of normal saline administered epidurally one to two hours before the end of surgery.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Morphine administered epidurally at different spinal levels (Th11-12, L2-3, caudal).
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Morphine administered epidurally.
Number of subjects: 45
Study: 6104564

Group type: EXPERIMENTAL
Intervention: Primidolol (50 mg or 100 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30296875

Group type: EXPERIMENTAL
Intervention: PREP pharmacist service
Number of subjects: 104
Study: 29969433

Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffold (BRS)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 366
Study: 27836933

Group type: EXPERIMENTAL
Intervention: Regorafenib (starting doses: 160 mg or lower)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Regorafenib (lower dose)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Regorafenib (overall treatment)
Number of subjects: 45
Study: 25569710

Group type: EXPERIMENTAL
Intervention: Affective message using affectively laden phrases
Number of subjects: 559

Group type: COMPARATOR
Intervention: Cognitive message using cognitively laden phrases
Number of subjects: 559
Study: 23298394

Group type: EXPERIMENTAL
Intervention: Radiofrequency-induced heat therapy (RFHT) for 30-60 seconds
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intralesional sodium stibogluconate (SSG) injections (50 mg cm(‐2) of lesion, seven injections)
Number of subjects: 100
Study: 20659937

Group type: EXPERIMENTAL
Intervention: Nystatin (1 ml suspension, 100,000 U/ml, every 8 h)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Fluconazole (3 mg/kg body weight, every third day)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 278
Study: 19074465

Group type: EXPERIMENTAL
Intervention: LB03002 at 0.2 mg/kg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: LB03002 at 0.5 mg/kg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: LB03002 at 0.7 mg/kg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: LB03002 at all doses
Number of subjects: 37
Study: 17685721

Group type: EXPERIMENTAL
Intervention: Tapering (TAP) for 4 weeks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Detraining (DTR) for 4 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 46
Study: 15050497

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 48

Group type: COMPARATOR
Intervention: No rescue treatment (Control)
Number of subjects: 48
Study: 11720096

Group type: EXPERIMENTAL
Intervention: 100 mg MDMA (first dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg MDMA (second dose, 4 hours after first)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg MDMA (second dose, 24 hours after first)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg MDMA (two doses, 4 hours apart)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg MDMA (two doses, 24 hours apart)
Number of subjects: 0
Study: 9340923

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (estrogen replacement therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 0
Study: 8432115

Group type: EXPERIMENTAL
Intervention: Side Port (SP) cardiac output measurements
Number of subjects: 31

Group type: COMPARATOR
Intervention: Central Venous Port (CVP) cardiac output measurements
Number of subjects: 31
Study: 3479456

Group type: EXPERIMENTAL
Intervention: Periodic subgingival irrigation with hydrogen peroxide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Periodic subgingival irrigation with chlorhexidine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Periodic subgingival irrigation with saline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Scaling and root planing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adjunctive irrigation with chlorhexidine or hydrogen peroxide
Number of subjects: 10
Study: 29446994

Group type: EXPERIMENTAL
Intervention: Individual acupuncture
Number of subjects: 46

Group type: COMPARATOR
Intervention: Group acupuncture
Number of subjects: 46
Study: 28262650

Group type: EXPERIMENTAL
Intervention: Cognitive training program + usual care (rehabilitation service)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 42
Study: 26016523

Group type: EXPERIMENTAL
Intervention: Dorsal decompression combined with the LimiFlex™ Paraspinous Tension Band (PSB)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Dorsal decompression only
Number of subjects: 63
Study: 23957458

Group type: EXPERIMENTAL
Intervention: Early surgery (operation within 3 days after onset of subarachnoid hemorrhage)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Intermediate surgery (operation from days 4 to 7)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Late surgery (operation after day 7)
Number of subjects: 99

Group type: COMPARATOR
Intervention: All groups (early, intermediate, late surgery)
Number of subjects: 99
Study: 21683046

Group type: EXPERIMENTAL
Intervention: AlcoholEdu for College (2-3 hour online course)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 30
Study: 18270832

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (2.5 mg and higher)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16148277

Group type: EXPERIMENTAL
Intervention: Predictive component in 2D catch-up saccade programming based on motion signals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Catch-up saccades characterized by large curvature or sudden change of direction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Position error available first
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retinal slip
Number of subjects: 0
Study: 15523305

Group type: EXPERIMENTAL
Intervention: unfractionated heparin or enoxaparin + IIb/IIIa inhibition
Number of subjects: 13800

Group type: EXPERIMENTAL
Intervention: bivalirudin + IIb/IIIa inhibition
Number of subjects: 13800

Group type: EXPERIMENTAL
Intervention: bivalirudin + provisional IIb/IIIa inhibition
Number of subjects: 13800

Group type: EXPERIMENTAL
Intervention: IIb/IIIa inhibitors (upstream drug initiation)
Number of subjects: 13800

Group type: EXPERIMENTAL
Intervention: IIb/IIIa inhibitors (during angioplasty only)
Number of subjects: 13800
Study: 11096335

Group type: EXPERIMENTAL
Intervention: Aversive classical conditioning paradigm with odors as unconditioned stimuli and faces as conditioned stimuli
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) during habituation, acquisition, and extinction
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cerebral activity analysis in individually defined cerebral regions
Number of subjects: 24
Study: 9308809

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonography
Number of subjects: 793

Group type: COMPARATOR
Intervention: Outpatient hysteroscopy
Number of subjects: 793
Study: 8374115

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR imaging (CE-MRI) with intravenous application of a contrast agent (0.1 mmol Gd-DTPA/kg)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR imaging (CE-MRI)
Number of subjects: 109
Study: 3330188

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Trental 400)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30661507

Group type: EXPERIMENTAL
Intervention: UPBEAT lifestyle intervention (tailored complex lifestyle intervention focused on improving diet and physical activity)
Number of subjects: 1158

Group type: COMPARATOR
Intervention: Standard antenatal care (control group)
Number of subjects: 1158

Group type: EXPERIMENTAL
Intervention: UPBEAT lifestyle intervention
Number of subjects: 1158
Study: 28755326

Group type: EXPERIMENTAL
Intervention: Intensive self-help intervention (62 web-based sessions, reminder e-mails, SMS)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Brief intervention (e-booklet about effects of alcohol)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Intensive self-help intervention
Number of subjects: 85

Group type: COMPARATOR
Intervention: Brief intervention
Number of subjects: 85
Study: 26409997

Group type: EXPERIMENTAL
Intervention: Retrograde brain perfusion
Number of subjects: 121

Group type: COMPARATOR
Intervention: Antegrade brain perfusion
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 121